
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is projected to increase product sales from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust revenue growth potential stemming from its expanding pipeline and product offerings. The company's recent $1.5 billion debt deal enhances its balance sheet, providing additional flexibility to navigate uncertainties and capitalize on future opportunities, while improvements in manufacturing efficiency are expected to help gross margins grow from 30% in 2023 back to 50% in 2025. Furthermore, encouraging clinical trial results in oncology and other therapeutic areas suggest solid prospects for long-term revenue growth, reinforced by valuable partnerships and a diverse portfolio of 35 mRNA development candidates.
Bears say
Moderna's financial outlook is negatively impacted by a significant decline in COVID vaccine sales, which are projected to drop from $18 billion in 2022 to $6.7 billion in 2023, with further reductions anticipated for 2025 due to waning vaccination rates. Additionally, the company faces competitive challenges in the respiratory vaccine market, particularly with its RSV product, mRESVIA, as successful alternatives have already been introduced. Furthermore, uncertainties surrounding its pipeline development outside of respiratory vaccines contribute to a decreased long-term revenue potential, leading to a reduction in the valuation of its COVID-related assets from $11.70 billion to $10.50 billion.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares